theMednet - What estimated absolute benefit level of adjuvant chemotherapy for HR-pos HER2-negative breast cancer is worth recommending chemotherapy to patients?

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Yale • NCI-CCC Breast Tumor Board Question • Breast Cancer, Non-metastatic

What estimated absolute benefit level of adjuvant chemotherapy for HR-pos HER2-negative breast cancer is worth recommending chemotherapy to patients?

For example, absolute benefit estimated from Oncotype DX reports